Experimental drug ACP-196 takes on recurrent glioblastoma

NCT ID NCT02586857

Ongoing Disease control Sponsor: Acerta Pharma BV Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called ACP-196 (acalabrutinib) in 24 adults with recurrent glioblastoma, an aggressive brain cancer that has returned after standard treatment. Participants take the drug by mouth once or twice daily. The main goal is to see if the drug can shrink tumors or stop them from growing, while also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ACP-196 (acalabrutinib)
What this could lead to: If successful, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is an early-phase trial with only 24 participants, so results may not apply broadly. The drug may not shrink tumors or improve survival, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Research Site

Los Angeles, California, 90095-1769, United States
Research Site

Palo Alto, California, 94304, United States
Research Site

Boston, Massachusetts, 02114, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

Boston, Massachusetts, 2215, United States
Research Site

New York, New York, 10021, United States
Research Site

Vancouver, Washington, 98684, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.